Which has better earnings and valuation, EXEL or QURE?

Exelixis has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 5.78 $782.57M $3.18 17.01 uniQure $18.67M 179.69 -$198.97M -$4.01 N/A

Is EXEL or QURE more profitable?

Exelixis has a net margin of 35.33% compared to uniQure's net margin of -1,350.73%. Exelixis' return on equity of 42.17% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% uniQure -1,350.73% -111.96% -29.01%

Does the media prefer EXEL or QURE?

In the previous week, Exelixis had 14 more articles in the media than uniQure. MarketBeat recorded 16 mentions for Exelixis and 2 mentions for uniQure. Exelixis' average media sentiment score of 1.18 beat uniQure's score of 0.48 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to QURE or BMRN?

In the previous week, BioMarin Pharmaceutical had 32 more articles in the media than uniQure. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 2 mentions for uniQure. BioMarin Pharmaceutical's average media sentiment score of 0.73 beat uniQure's score of 0.48 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BioMarin Pharmaceutical 13 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARWR or QURE?

In the previous week, Arrowhead Pharmaceuticals had 13 more articles in the media than uniQure. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 2 mentions for uniQure. Arrowhead Pharmaceuticals' average media sentiment score of 0.90 beat uniQure's score of 0.48 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to HALO or QURE?

In the previous week, Halozyme Therapeutics had 13 more articles in the media than uniQure. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 2 mentions for uniQure. Halozyme Therapeutics' average media sentiment score of 1.04 beat uniQure's score of 0.48 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MDGL or QURE?

In the previous week, Madrigal Pharmaceuticals had 5 more articles in the media than uniQure. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 2 mentions for uniQure. Madrigal Pharmaceuticals' average media sentiment score of 1.08 beat uniQure's score of 0.48 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

uniQure (QURE) Competitors

$48.37 -0.52 (-1.06%)

As of 08/21/2026 04:00 PM Eastern

Compare

QURE vs. EXEL, BMRN, ARWR, HALO, and MDGL

Should you buy uniQure stock or one of its competitors? uniQure's main competitors and comparable companies include Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Arrowhead Pharmaceuticals (ARWR), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does uniQure compare to Exelixis?

Exelixis (NASDAQ:EXEL) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Exelixis currently has a consensus price target of $50.07, suggesting a potential downside of 7.42%. uniQure has a consensus price target of $65.00, suggesting a potential upside of 34.38%. Given uniQure's stronger consensus rating and higher possible upside, analysts plainly believe uniQure is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

Exelixis has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, uniQure has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Exelixis had 14 more articles in the media than uniQure. MarketBeat recorded 16 mentions for Exelixis and 2 mentions for uniQure. Exelixis' average media sentiment score of 1.18 beat uniQure's score of 0.48 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	11 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exelixis has a net margin of 35.33% compared to uniQure's net margin of -1,350.73%. Exelixis' return on equity of 42.17% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
uniQure	-1,350.73%	-111.96%	-29.01%

Exelixis has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.78	$782.57M	$3.18	17.01
uniQure	$18.67M	179.69	-$198.97M	-$4.01	N/A

Summary

Exelixis beats uniQure on 11 of the 17 factors compared between the two stocks.

How does uniQure compare to BioMarin Pharmaceutical?

uniQure (NASDAQ:QURE) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

BioMarin Pharmaceutical has a net margin of 2.14% compared to uniQure's net margin of -1,350.73%. BioMarin Pharmaceutical's return on equity of 5.32% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

78.8% of uniQure shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 4.7% of uniQure shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioMarin Pharmaceutical has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$18.67M	179.69	-$198.97M	-$4.01	N/A
BioMarin Pharmaceutical	$3.22B	4.01	$348.90M	$0.37	180.27

In the previous week, BioMarin Pharmaceutical had 32 more articles in the media than uniQure. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 2 mentions for uniQure. BioMarin Pharmaceutical's average media sentiment score of 0.73 beat uniQure's score of 0.48 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioMarin Pharmaceutical	13 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

uniQure currently has a consensus target price of $65.00, suggesting a potential upside of 34.38%. BioMarin Pharmaceutical has a consensus target price of $88.83, suggesting a potential upside of 33.17%. Given uniQure's higher probable upside, equities research analysts clearly believe uniQure is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75

uniQure has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Summary

BioMarin Pharmaceutical beats uniQure on 13 of the 17 factors compared between the two stocks.

How does uniQure compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to uniQure's net margin of -1,350.73%. Arrowhead Pharmaceuticals' return on equity of -60.06% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
uniQure	-1,350.73%	-111.96%	-29.01%

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals has higher revenue and earnings than uniQure. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.79	-$1.63M	-$2.25	N/A
uniQure	$18.67M	179.69	-$198.97M	-$4.01	N/A

In the previous week, Arrowhead Pharmaceuticals had 13 more articles in the media than uniQure. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 2 mentions for uniQure. Arrowhead Pharmaceuticals' average media sentiment score of 0.90 beat uniQure's score of 0.48 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arrowhead Pharmaceuticals presently has a consensus price target of $97.33, indicating a potential upside of 11.74%. uniQure has a consensus price target of $65.00, indicating a potential upside of 34.38%. Given uniQure's stronger consensus rating and higher probable upside, analysts plainly believe uniQure is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, uniQure has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

Summary

Arrowhead Pharmaceuticals beats uniQure on 9 of the 16 factors compared between the two stocks.

How does uniQure compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

Halozyme Therapeutics has a net margin of 24.86% compared to uniQure's net margin of -1,350.73%. Halozyme Therapeutics' return on equity of 260.98% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
uniQure	-1,350.73%	-111.96%	-29.01%

Halozyme Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, uniQure has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

Halozyme Therapeutics currently has a consensus target price of $91.20, suggesting a potential downside of 15.69%. uniQure has a consensus target price of $65.00, suggesting a potential upside of 34.38%. Given uniQure's stronger consensus rating and higher possible upside, analysts clearly believe uniQure is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Halozyme Therapeutics had 13 more articles in the media than uniQure. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 2 mentions for uniQure. Halozyme Therapeutics' average media sentiment score of 1.04 beat uniQure's score of 0.48 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Halozyme Therapeutics has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.66B	7.38	$316.89M	$3.35	32.29
uniQure	$18.67M	179.69	-$198.97M	-$4.01	N/A

Summary

Halozyme Therapeutics beats uniQure on 10 of the 16 factors compared between the two stocks.

How does uniQure compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

In the previous week, Madrigal Pharmaceuticals had 5 more articles in the media than uniQure. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 2 mentions for uniQure. Madrigal Pharmaceuticals' average media sentiment score of 1.08 beat uniQure's score of 0.48 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Madrigal Pharmaceuticals has a net margin of -25.32% compared to uniQure's net margin of -1,350.73%. Madrigal Pharmaceuticals' return on equity of -56.65% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
uniQure	-1,350.73%	-111.96%	-29.01%

Madrigal Pharmaceuticals currently has a consensus target price of $689.93, indicating a potential upside of 33.52%. uniQure has a consensus target price of $65.00, indicating a potential upside of 34.38%. Given uniQure's higher probable upside, analysts clearly believe uniQure is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

uniQure has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	12.45	-$288.28M	-$12.89	N/A
uniQure	$18.67M	179.69	-$198.97M	-$4.01	N/A

Madrigal Pharmaceuticals has a beta of -1.01, suggesting that its stock price is 201% less volatile than the broader market. Comparatively, uniQure has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

Summary

Madrigal Pharmaceuticals beats uniQure on 10 of the 16 factors compared between the two stocks.

Get uniQure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QURE vs. The Competition

Export

Metric	uniQure	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.36B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-12.06	11.62	272.88	24.24
Price / Sales	179.69	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	10.36	16.80	13.05	6.20
Net Income	-$198.97M	-$12.50M	$3.47B	$348.59M
7 Day Performance	-0.51%	3.29%	2.09%	0.08%
1 Month Performance	22.67%	8.23%	6.64%	3.88%
1 Year Performance	208.09%	55.05%	25.02%	16.98%

uniQure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QURE uniQure	2.9025 of 5 stars	$48.37 -1.1%	$65.00 +34.4%	+208.1%	$3.36B	$18.67M	N/A	500
EXEL Exelixis	3.3988 of 5 stars	$54.08 +0.7%	$50.07 -7.4%	+40.0%	$13.30B	$2.32B	17.01	1,077	News Coverage Positive News Analyst Forecast
BMRN BioMarin Pharmaceutical	4.7599 of 5 stars	$66.70 -1.4%	$88.83 +33.2%	+13.9%	$13.10B	$3.22B	180.27	3,221	Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.2776 of 5 stars	$87.11 -0.4%	$97.33 +11.7%	+308.4%	$12.32B	$669.50M	N/A	400	News Coverage Insider Trade
HALO Halozyme Therapeutics	3.8838 of 5 stars	$108.17 +1.9%	$91.20 -15.7%	+50.6%	$12.04B	$1.40B	32.29	390	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QURE) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

uniQure (QURE) Competitors

QURE vs. EXEL, BMRN, ARWR, HALO, and MDGL

How does uniQure compare to Exelixis?

Summary

How does uniQure compare to BioMarin Pharmaceutical?

Summary

How does uniQure compare to Arrowhead Pharmaceuticals?

Summary

How does uniQure compare to Halozyme Therapeutics?

Summary

How does uniQure compare to Madrigal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

uniQure (QURE) Competitors

QURE vs. EXEL, BMRN, ARWR, HALO, and MDGL

How does uniQure compare to Exelixis?

Do analysts prefer EXEL or QURE?

Which has more volatility & risk, EXEL or QURE?

Do insiders and institutionals have more ownership in EXEL or QURE?

Does the media prefer EXEL or QURE?

Is EXEL or QURE more profitable?

Which has better earnings and valuation, EXEL or QURE?

Summary

How does uniQure compare to BioMarin Pharmaceutical?

Is QURE or BMRN more profitable?

Do institutionals and insiders hold more shares of QURE or BMRN?

Which has preferable valuation and earnings, QURE or BMRN?

Does the media refer more to QURE or BMRN?

Do analysts recommend QURE or BMRN?

Which has more volatility & risk, QURE or BMRN?

Summary

How does uniQure compare to Arrowhead Pharmaceuticals?

Is ARWR or QURE more profitable?

Do institutionals and insiders believe in ARWR or QURE?

Which has preferable valuation and earnings, ARWR or QURE?

Does the media refer more to ARWR or QURE?

Do analysts rate ARWR or QURE?

Which has more risk and volatility, ARWR or QURE?

Summary

How does uniQure compare to Halozyme Therapeutics?

Is HALO or QURE more profitable?

Which has more volatility and risk, HALO or QURE?

Do analysts recommend HALO or QURE?

Does the media refer more to HALO or QURE?

Do institutionals & insiders have more ownership in HALO or QURE?

Which has better earnings & valuation, HALO or QURE?

Summary

How does uniQure compare to Madrigal Pharmaceuticals?

Does the media refer more to MDGL or QURE?

Is MDGL or QURE more profitable?

Do analysts rate MDGL or QURE?

Do insiders and institutionals believe in MDGL or QURE?

Which has higher valuation & earnings, MDGL or QURE?

Which has more volatility and risk, MDGL or QURE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools